Related Experiment Video
Updated: Oct 26, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?
1David Geffen School of Medicine, University of California Los Angeles, CA.
Abstract:
Breast cancer that is characterized by amplification or over expression of human epidermal growth factor receptor 2 (HER2) accounts for 15% to 20% of all forms of the disease. Although HER2 amplification has been associated with aggressive disease behavior and poor prognosis, the development and availability of a number of HER2-targeted agents has led to improved outcomes for patients with HER2-positive metastatic breast cancer, with data suggesting that overall survival has substantially improved in the past 2 decades. An increasing proportion of HER2-positive metastatic breast cancer is diagnosed as de novo stage IV disease. Patients with de novo metastases are traditionally classified in the general category of metastatic breast cancer and not analyzed as a distinct subgroup, though response to therapy and disease outcomes may differ from that of disease that recurred after early stage disease. Among patients with HER2+ de novo metastatic breast cancer, those who achieve a complete response have a prolonged progression-free survival and overall survival. Moreover, the fact that some patients achieve a prolonged durable response has raised interest and renewed discussion about whether cure is feasible in the complex context of metastatic breast cancer. In this review, available data associated with the possibility of cure in the population of patients with HER2+ de novo metastatic breast cancer are presented and discussed in detail.
Insights
Cure may be possible for some patients with HER2-positive de novo metastatic breast cancer. Achieving a complete response significantly improves survival for these patients, prompting renewed discussion on treatment goals.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Medicine
Background:
- HER2-positive breast cancer, comprising 15-20% of cases, is linked to aggressive behavior.
- Targeted therapies have significantly improved survival for HER2-positive metastatic breast cancer over the last two decades.
- De novo stage IV HER2-positive breast cancer is an increasing concern, with potentially different outcomes than recurrent disease.
Purpose of the Study:
- To review and discuss the feasibility of achieving a cure in patients with HER2-positive de novo metastatic breast cancer.
- To analyze the impact of complete response on progression-free and overall survival in this specific patient subgroup.
Main Methods:
- Review of available data and clinical outcomes.
- Analysis of patient responses to HER2-targeted therapies.
- Discussion of factors influencing durable responses and potential for cure.
Main Results:
- Complete response in HER2+ de novo metastatic breast cancer correlates with prolonged progression-free and overall survival.
- Durable responses observed in some patients suggest potential for long-term disease control.
- HER2-targeted agents have substantially improved survival in HER2-positive metastatic breast cancer.
Conclusions:
- The possibility of cure for HER2-positive de novo metastatic breast cancer warrants further investigation.
- Achieving complete response is a critical factor for long-term survival in this population.
- Distinct analysis of de novo metastatic disease is crucial for understanding treatment efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...